Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
L Boiron, E Joura, N Largeron, B Prager… - BMC Infectious …, 2016 - Springer
Background HPV is a major cancer-causing factor in both sexes in the cervix, vulva, vagina,
anus, penis, oropharynx as well as the causal factor in other diseases such as genital warts …
anus, penis, oropharynx as well as the causal factor in other diseases such as genital warts …
Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model
D Schobert, V Remy, O Schoeffski - Health economics review, 2012 - Springer
Introduction Persistent infections with human papillomavirus (HPV) are a necessary cause of
cervical cancer and are responsible for important morbidity in men and women. Since 2007 …
cervical cancer and are responsible for important morbidity in men and women. Since 2007 …
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
FS Mennini, P Bonanni, F Bianic, C de Waure… - Cost Effectiveness and …, 2017 - Springer
Abstract Background In Italy HPV vaccination with the quadrivalent vaccine (Gardasil®) is
offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine …
offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine …
Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and …
J Olsen, TR Jørgensen - Cost Effectiveness and Resource Allocation, 2015 - Springer
Objective The purpose of this study was to assess the consequences of a national
immunization program with HPV vaccine for both boys and girls in Denmark, including the …
immunization program with HPV vaccine for both boys and girls in Denmark, including the …
Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost–effectiveness analysis
X Bresse, C Goergen, B Prager… - Expert review of …, 2014 - Taylor & Francis
The International Agency for Research on Cancer acknowledges that HPV is a human
carcinogen affecting both sexes. This study aimed to evaluate the public health impact of …
carcinogen affecting both sexes. This study aimed to evaluate the public health impact of …
Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model
EJ Dasbach, N Largeron… - Expert Review of …, 2008 - Taylor & Francis
To assess the epidemiological and economic impact of alternative quadrivalent human
papillomavirus (HPV) vaccine strategies in Norway, we adapted a previously published …
papillomavirus (HPV) vaccine strategies in Norway, we adapted a previously published …
Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
J De La Fuente, JJ Hernandez Aguado… - Human vaccines & …, 2019 - Taylor & Francis
Human papillomavirus (HPV) is one of the main causes of infection-related cancer. The
bivalent vaccine (2vHPV)(16/18) and quadrivalent (6/11/16/18) HPV vaccine (4vHPV) have …
bivalent vaccine (2vHPV)(16/18) and quadrivalent (6/11/16/18) HPV vaccine (4vHPV) have …
Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in …
AB Kind, A Pavelyev, S Kothari, N El Mouaddin… - BMC Public Health, 2020 - Springer
Background An infection with high-risk human papillomavirus (HPV) is the obligatory
aetiological factor for the development of cervical cancer. In Switzerland, the prevention …
aetiological factor for the development of cervical cancer. In Switzerland, the prevention …
Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe
R Marty, S Roze, X Bresse, N Largeron, J Smith-Palmer - BMC cancer, 2013 - Springer
Background HPV is related to a number of cancer types, causing a considerable burden in
both genders in Europe. Female vaccination programs can substantially reduce the …
both genders in Europe. Female vaccination programs can substantially reduce the …
Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland
TD Szucs, N Largeron, KJ Dedes, R Rafia… - … medical research and …, 2008 - Taylor & Francis
Objective: Based on positive safety and efficacy data, a quadrivalent Human PapillomaVirus
(HPV) vaccine has been approved in Switzerland to prevent HPV types 6, 11, 16 and 18 …
(HPV) vaccine has been approved in Switzerland to prevent HPV types 6, 11, 16 and 18 …
相关搜索
- universal vaccination programme
- cost effectiveness hpv vaccine
- quadrivalent hpv vaccine
- nonavalent hpv vaccine
- cervical cancer vaccination programme
- public health hpv vaccine
- hpv vaccination diseases in males
- cost effectiveness diseases in males
- epidemiological impact hpv vaccine
- cost effectiveness epidemiological impact
- virus circulation hpv vaccine
- effectiveness analysis universal vaccination
- public health effectiveness analysis
- public health virus circulation
- cost effectiveness vaccination programme
- cervical cancer hpv vaccine